Caribou Biosciences, Inc. specializes in the research and development of tools and technologies for cellular engineering and
analysis. Caribou Bio’s technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. Caribou Bio’s lead technology is the Cas9 enzyme, a highly
efficient and easy to use genome editing platform that does not require unique protein development. Cas9-based editing permits multiplex genome engineering by targeting multiple genomic sites in a
single experimental step. Caribou Bio’s research tools and technologies will provide transformative capabilities to basic and applied research and development in the drug development, agricultural
biotechnology, and industrial biosciences fields.